News

ORMD-0801 is an orally ingestible insulin capsule indicated for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease

The new lab allows the company to better support the business needs of its clients by increasing efficiency during discovery and development, and providing consistency in the stages

The company has received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate, which is the generic

Nemonoxacin is the first pharmaceutical product to be included in Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs of the Economic Cooperation Framework Agreement (ECFA) between Taiwan

OneSource strategic lab solutions will deliver PerkinElmer’s informatics, instrumentation, service and process optimization, to increase laboratories’ productivity and performance. Due to limited access to laboratory personnel, the information

The company along with the National Research Council Canada have identified the potential of sCLU in inducing EMT. EMT mechanism plays a key role in tumor invasion and

The LUX-Lung 6 trial has shown that patients with epidermal epidermal growth factor receptor (EGFR or ErbB1) mutation-positive advanced NSCLC treated first-line with afatinib lived for almost a

The contract is funded by the Defense Threat Reduction Agency (DTRA). According to the terms of the company’s contract with the Science and Technology Corporation, anti-ricin antibodies will

The first and only subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy is approved to induce and maintain clinical response and improve endoscopic appearance of the mucosa during induction.